Skip to main content
Journal of Orthopaedics and Traumatology

Official Journal of the Italian Society of Orthopaedics and Traumatology

Table 5 4- and 8-week post-treatment mechanical testing (treated femur values normalized to normal (contralateral) side, one-way ANOVA to compare all four groups at 4 and 8 weeks)

From: The effect of locally delivered recombinant human bone morphogenetic protein-2 with hydroxyapatite/tri-calcium phosphate on the biomechanical properties of bone in diabetes-related osteoporosis

Groups

Percent maximum torque to failure

p value

Percent torsional rigidity

p value

Percent maximum shear stress

p value

Percent shear modulus

p value

Saline

 4 weeks (n = 5)

107 ± 12

0.20

110 ± 29

0.12

100 ± 14

0.25

103 ± 29

0.53

 8 weeks (n = 8)

83 ± 18

0.01

106 ± 25

0.85

82 ± 17

0.02

105 ± 34

0.73

Buffer + HA/TCP

 4 weeks (n = 6)

102 ± 17

 

85 ± 26

 

115 ± 21

 

95 ± 31

 

 8 weeks (n = 6)

117 ± 17

 

111 ± 18

 

106 ± 11

 

97 ± 15

 

Low-dose rh-BMP-2 + HA/TCP

 4 weeks (n = 5)

116 ± 22*

 

118 ± 17*

 

117 ± 20*

 

115 ± 19*

 

 8 weeks (n = 6)

115 ± 24

 

98 ± 19

 

107 ± 22

 

89 ± 12

 

High-dose rh-BMP-2 + HA/TCP

 4 weeks (n = 6)

123 ± 21*

 

116 ± 27*

 

124 ± 33*

 

118 ± 39*

 

 8 weeks (n = 6)

105 ± 19

 

102 ± 40

 

106 ± 12

 

100 ± 33

 
  1. Treated femur values normalized to untreated (contralateral) side; one-way ANOVA comparing all four groups at 4 and 8 weeks (mean ± standard deviation)
  2. p value in bold indicates statistical significance
  3. * Indicates a noticeable dose dependent trend in all four mechanical properties, although no statistical significance exists.
Back to article page